2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.05 Long Term Follow-up of Two Decades Experience with Neoadyuvant Chemotherapy in Resectable Non Small Cell Lung Cancer

EP.08D.05 Long Term Follow-up of Two Decades Experience with Neoadyuvant Chemotherapy in Resectable Non Small Cell Lung Cancer

Back to course

Pdf Summary

The study conducted by Mónica Antoñanzas and colleagues at Hospital Clínico San Carlos in Madrid, Spain, evaluates the long-term outcomes of neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC) over two decades. This investigation focuses on Stage II and III NSCLC patients who received preoperative chemotherapy followed by complete tumor resection between January 1999 and December 2019.<br /><br />Out of 186 patients treated, a significant pathological response, either a pathological complete response (pCR) or major pathological response (MPR), was observed in 32.7% of the cohort. Specifically, 22 patients achieved pCR, and 37 achieved MPR. These responses are correlated with improved survival outcomes; those achieving pCR had better overall survival (OS) and event-free survival (EFS) rates at 2, 5, and 10 years compared to those who did not achieve pCR. The OS rates were significantly higher for the pCR group, with a 10-year OS of 45%, compared to 29% for the non-pCR group.<br /><br />For the MPR group, Kaplan-Meier estimates also showed superior EFS and OS at 2, 5, and 10 years. Notably, a 10-year OS rate was 55% for those with MPR compared to 24.1% without. The study highlights a strong association between pathological response and long-term survival, indicating that patients achieving pCR or MPR enjoy enhanced survival benefits.<br /><br />In conclusion, the research underscores the enhanced survival outcomes associated with achieving pCR and MPR in NSCLC through neoadjuvant chemotherapy. It suggests the potential benefits of integrating immune-based neoadjuvant strategies, as emerging treatments show promising pCR rates. This long-term study provides vital insight into optimizing treatment strategies for improved patient survival.

Asset Subtitle

Monica Antoñanzas

Meta Tag

Speaker Monica Antoñanzas

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

neoadjuvant chemotherapy

non-small cell lung cancer

NSCLC

pathological complete response

major pathological response

overall survival

event-free survival

long-term outcomes

immune-based strategies

treatment optimization